Deuterated buprenorphine as a protective agent for fetal subjects against full-agonist opioid exposure
AssigneeBioVentures, LLC
InventorsLisa BRENTS, Julia TOBACYK, Peter CROOKS, Venumadhav JANGANATI
Life of this patent
Estimating the term…
Abstract
Disclosed herein is deuterated buprenorphine as a protective agent for fetal subjects against full-agonist opioid exposure. Use of deuterated buprenorphine prevents or reduces exposure of the fetus to opioids used by the mother. Use of deuterated buprenorphine may prevent or reduces exposure of the fetus to harmful metabolites of buprenorphine.
Claims28
A method for fetal protection against full agonist opioid exposure, the method comprising administering a deuterated buprenorphine, or a pharmaceutically acceptable salt thereof, to a maternal subject during the maternal subject's pregnancy or in anticipation of the maternal subject's pregnancy.
(canceled)
(canceled)
(canceled)
A method for fetal protection, the method comprising administering a deuterated buprenorphine to a fetal subject.
(canceled)
(canceled)
(canceled)
A pharmaceutical composition comprising an effective amount of deuterated buprenorphine and a pharmaceutically acceptable carrier, excipient, or diluent.
-32. (canceled)
Dependencies are inferred from the claim text.